BioCentury | May 30, 2020
Translation in Brief

Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

Brain cancer CAR T therapy  A McMaster University and University of Toronto team revealed in a Cell Stem Cell paper proof-of-concept data for Empirica Therapeutics’ lead product eCAR-133, a CAR T cell therapy targeting PROM1....
BC Week In Review | Mar 2, 2018
Clinical News

Senhwa reports Phase I data for CX-5461 in hematologic malignancies

Senhwa Biosciences Inc. (TPEx:6492) reported data from 16 evaluable patients with advanced hematologic malignancies in a dose-escalation Phase I trial showing that IV CX-5461 led to one partial response in a patient with anaplastic large...
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
BC Innovations | May 31, 2017
Translation in Brief

Supporting structures

A recent study from Dana-Farber Cancer Institute has two key ingredients for a new PARP-related opportunity in cancer. The findings marry the now-hot field of synthetic lethality with the growing momentum in targeting specialized DNA...
BC Innovations | Feb 13, 2014
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer RNA polymerase I (Pol I) In vitro studies identified a small molecule that causes the degradation of the RPA194 catalytic...
BC Extra | Dec 14, 2013
Financial News

Senhwa raises $17 million in series B

Cancer company Senhwa Biosciences Inc. (New Taipei City, Taiwan) raised $17 million in a series B round from existing and new investors including H&Q Asia Pacific; Morningside; and China Investment & Development. Senhwa's CX-5461 , a...
BC Week In Review | Mar 18, 2013
Company News

Cylene Pharmaceuticals, TetraGene deal

Cylex granted TetraGene an option to acquire exclusive, worldwide rights to Cylene's associated anticancer quadruplex-targeting technologies, including Quarfloxin. Cylex will receive an undisclosed upfront fee and is eligible for milestones and royalties. Quarfloxin, which is...
BC Innovations | Aug 2, 2012
Cover Story

Cylene takes pol position in cancer

Australian and U.S. researchers have shown that a small molecule inhibitor of RNA polymerase I blocked tumor growth in mouse models of lymphoma. 1 Cylene Pharmaceuticals Inc. and the Peter MacCallum Cancer Centre plan to...
BC Innovations | Aug 2, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lymphoma; leukemia RNA polymerase I (Pol I) Cell culture and mouse studies suggest inhibitors of Pol I could help treat hematological cancers. In a panel...
BC Week In Review | Jul 16, 2012
Clinical News

Cylene Pharmaceuticals preclinical data

In a mouse model of lymphoma, a single oral dose CX-5461 significantly reduced tumor burden in lymph nodes (p<0.01) and significantly reduced spleen size (p<0.001) at 24 hours post-treatment vs. vehicle-treated controls. Additionally, 50 mg/kg...
Items per page:
1 - 10 of 10